UCB.BR BE Equity☆

Pricefull chart →

Mkt cap $53.04B · P/E (FY) 44.9× · 1Y +38.3% · Off 52W high −15.1% · Vol (1Y) 35.3%

Key fundamentalsfull statements →

UCB SA is a biopharmaceutical company that develops products for people with neurology and immunology diseases worldwide. Its marketed treatments include Cimzia for inflammatory conditions, Vimpat, Keppra, and Briviact for epilepsy, Neupro for Parkinson's disease, Evenity for osteoporosis, and Bimzelx for psoriasis and related disorders, among others. The company also has a pipeline spanning Alzheimer's disease, lupus, and additional indications, and engages in contract manufacturing. It was incorporated in 1925 and is headquartered in Brussels, Belgium.

Snapshot

Headline riskfull risk →

Peers

No same-industry peers in the universe for UCB.BR.